ATRI's Michael C. Donohue, Ph.D., Rema Raman, Ph.D., and Michael S. Rafii, MD, PHD, recently had their study "Trial of Solanezumab in Preclinical Alzheimer’s Disease" published in The New England Journal of Medicine.
Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. Solanezumab specifically targets monomeric amyloid in persons with elevated brain amyloid levels, and by targeting this specific form of amyloid, it aims to slow down cognitive decline in individuals with preclinical Alzheimer's disease.
While the phase 3 trial did not show a significant cognitive benefit, the trial's findings offer valuable insights into the potential of Solanezumab to modify the underlying pathology of Alzheimer's disease. Continued research and development in this area hold great promise for the future of Alzheimer's medication.
